View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 29, 2018

CVS Health completes acquisition of Aetna for $69bn

CVS Health has completed its previously announced acquisition of all outstanding shares of healthcare benefits provider Aetna in a deal valued at $69bn.

CVS Health has completed its acquisition of all outstanding shares of healthcare benefits provider Aetna in a deal valued at $69bn.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

Under the agreement, the total value of the transaction announced in December last year will amount to $78bn, including the assumption of Aetna’s debt.

Following the acquisition, the combined company will connect consumers with health resources of CVS Health in communities across the US and Aetna’s network of providers.

CVS Health president and CEO Larry Merlo said: “By delivering the combined capabilities of our two leading organisations, we will transform the consumer health experience and build healthier communities through a new innovative healthcare model that is local, easier to use, less expensive and puts consumers at the centre of their care.

“By fully integrating Aetna’s medical information and analytics with CVS Health’s pharmacy data, we can develop new ways to engage consumers in their total health and wellness through personal contacts and deeper collaboration with their primary care physicians.

“As a result, we expect patients will benefit from earlier interventions and better-connected care, leading to improved health outcomes and lower medical costs.”

“We expect patients will benefit from earlier interventions and better-connected care, leading to improved health outcomes and lower medical costs.”

The combined company will develop new products and services that will be broadly available to the healthcare marketplace.

Retail pharmacy services, speciality pharmacy and long-term care, walk-in clinical services and PBM services

CVS Health offerings such as retail pharmacy services, speciality pharmacy and long-term care, walk-in clinical services and PBM services will continue to be fully accessible to other health plans.

Going forward, the company plans to introduce programmes and services to increase access to care and help improve health outcomes.

These programmes, in particular, are expected to target better management of chronic disease using the networks and technology.

The company is also developing new medical cost reduction programmes to bring out improvement in medication adherence and avoid hospital readmissions.

The cash portion of the acquisition was funded by CVS Health through existing cash on hand and debt financing.

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology